a d Rituxan for Chronic GVHD | Oncolink - Cancer Resources

Rituxan for Chronic GVHD

Ultima Vez Modificado: 29 de enero del 2006

Share article


Dear OncoLink "Ask The Experts,"

My brother has chronic GVHD and all other treatments have failed so far. His doctor now has decided to try Rituximab. What can you tell me about this?


Deana Potts, MSN, CRNP, Advanced Practice Oncology Nurse, responds:

B-cells and T-cells are part of the immune system. GVHD, or graft versus host disease, is caused by donor T-cells that see the recipient as foreign and thus attack the recipient. Rituximab is a medication that is actually directed against B-cells. It is believed that you need B cells in order to activate T cells. So by removing the B cells with Rituximab, the T cells become less functional and therefore may mount less of a graft versus host response.

Rituximab is being used in limited cases, and should be considered somewhat "investigational" in this setting. Although it is safe, the response rate is largely unknown. It is a reasonable alternative when traditional therapies are not working.

I Wish You Knew

Understanding prostate cancer screening

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información